KO
44
2
FCX
44
4
ITW
45
2
PDCO
77
3
PPL
44
9
MAT
41
2
BK
60
2
CI
35
2
PNC
48
6
T
32
2
PCG
59
9
NI
63
5
JNJ
30
4
O
26
16
AMP
43
2
PX
56
3
MPC
28
3
SLG
37
6
NTRS
35
10
CSCO
63
5
KO
44
2
FCX
44
4
ITW
45
2
PDCO
77
3
PPL
44
9
MAT
41
2
BK
60
2
CI
35
2
PNC
48
6
T
32
2
PCG
59
9
NI
63
5
JNJ
30
4
O
26
16
AMP
43
2
PX
56
3
MPC
28
3
SLG
37
6
NTRS
35
10
CSCO
63
5
Financhill
Back

Xeris Biopharma Holdings 10K Form

Buy
74

XERS
Xeris Biopharma Holdings

Last Price:
$3.49
Seasonality Move:
-18.08%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-10 10Q XERS/Xeris Biopharma Holdings Quarterly
2020-05-07 10Q XERS/Xeris Biopharma Holdings Quarterly
2020-03-12 10K XERS/Xeris Biopharma Holdings Annual
2019-11-07 10Q XERS/Xeris Biopharma Holdings Quarterly
2019-08-06 10Q XERS/Xeris Biopharma Holdings Quarterly
2019-05-09 10Q XERS/Xeris Biopharma Holdings Quarterly

Receive XERS News And Ratings

See the #1 stock for the next 7 days that we like better than XERS

XERS Financial Statistics

Sales & Book Value

Annual Sales: $163.9M
Cash Flow: $-8.4M
Price / Cash Flow: 0
Annual Sales: $-0.19
Price / Book: 0

Profitability

EPS (TTM): -0.44000
Net Income (TTM): $-63.1M
Gross Margin: $135.3M
Return on Equity: -1019.2%
Return on Assets: -19.24%

Xeris Biopharma Holdings Earnings Forecast

Key Xeris Biopharma Holdings Financial Ratios

  • The Gross Profit Margin over the past 8 years for XERS is 82.52%.
  • The Selling, General & Administrative Expenses for XERS have been equal to 89.13% of Gross Profit Margin.
  • The Research & Development expenses have been 13.63% of Revenue.
  • The Interest Expense is -42.74% of Operating Income.
  • The Net Earning history of XERS is -37.98% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 6 years.

Xeris Biopharma Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: XERS
CUSIP: 98422L
Website: xerispharma.com

Debt

Debt-to-Equity Ratio: -8.17
Current Ratio: 1.79
Quick Ratio: 1.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

XERS Technical Analysis vs Fundamental Analysis

Buy
74
Xeris Biopharma Holdings (XERS) is a Buy

Is Xeris Biopharma Holdings a Buy or a Sell?